MyelinWatch EL
← Pipeline
Human clinical dataTerminated / stoppedNegative

Phase 3 • terminated

RESTORE

Clemastine • INO in MS

Practical availability: Research record — not presented as established care

Compound / intervention
Clemastine • INO in MS
Mechanism
Clemastine; muscarinic-receptor antagonism
Development stage
Phase 3 • terminated
Status
Terminated after a futility no-go analysis
Evidence level
Human Phase 3 • terminated after futility analysis amid slow recruitment
Next substantive checkpoint

The decision followed slow recruitment and futility analysis; it is not by itself definitive proof that clemastine is ineffective

ClinicalTrials.govOpen source ↗Last checked: 16 Sep 2026

Related substantive developments

Human clinical dataTerminated / stoppedNegative

Phase 3

RESTORE: Phase 3 clemastine study terminated after a futility no-go analysis

RESTORE, which tested clemastine in people with MS and internuclear ophthalmoparesis, was terminated. The registry says slow recruitment led to a futility analysis with a no-go outcome.

Practical availability: Research record — not presented as established care

What this means clinically

This is an important negative development for this study, but it should not be presented as a clean efficacy result: the decision followed a futility analysis in a trial with serious recruitment difficulty.

Source quality: High • ClinicalTrials.gov registry status

ClinicalTrials.govClinicalTrials.gov ↗